DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE) – Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania against Ocugen, Inc. (NASDAQ: OCGN) on behalf of those who purchased or otherwise acquired publicly traded securities of Ocugen between February 2, 2021 and June 10, 2021 inclusive (the “Class Period”). Investors have until August 17, 2021 to apply to the court to be named as the main plaintiff in the legal dispute.

Click here to take part in the promotion.

On May 26, 2021, Ocugen announced that it intends to submit an application to the FDA for an Emergency Authorization (EUA) for COVAXIN, a COVID-19 vaccine, in June 2021. On June 10, 2021, Ocugen announced that it “will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN”, but will instead “submit a biologics license application (BLA) for its COVID-19 vaccine candidate COVAXIN follow”. The chairman and CEO of Ocugen stated, “Although we were close to finalizing our EUA filing, we received a recommendation from the FDA to follow a BLA path” and that “doing so will extend our deadlines.”

Ocugen stock lost more than 24% in intraday trading on the same day, based on this news.

On June 10, 2021, the company announced that it would no longer seek EUAs for Covaxin and would instead apply for full US approval of the shot.

As a result of this news, the stock price plummeted, closing at $ 6.69 per share on June 11, 2021, a 25.17% decrease from the June 10, 2021 closing price of $ 9.31 per share.

Ocugen’s class action alleges that during the class action period the defendants made false and misleading information and failed to disclose: EUA; (ii) Ocugen would not file an EEA with the FDA; and (iii) as a result, Ocugen’s financial statements and Defendants’ statements about Ocugen’s business, operations and prospects were false, misleading and / or unfounded.

If you have bought or otherwise acquired Ocugen stock and have suffered a loss, are a long-term shareholder, have information, want to learn more about these claims, or have questions about this release or your rights or interests in relation to these matters, please contact Brandon Walker, Melissa Fortunato or Marion Passmore by email at [email protected], by phone at (212) 355-4648, or by completing this contact form. There are no costs or obligations for you.

About Bragar Eagle & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York, California and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation in state and federal courts across the country. More information about the company can be found at www.bespc.com. Lawyer advertising. Previous results do not guarantee similar results.